Singular Health Group Ltd (AU:SHG)
ASX:SHG
Want to see AU:SHG full AI Analyst Report?
Top Page
Singular Health Group Ltd
(Sydney:SHG)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.21
▼(-18.46% Downside)
Action:ReiteratedDate:01/10/26
The score is driven primarily by weak financial performance (large losses, shrinking revenue in 2025, and ongoing cash burn) despite an improved latest-period balance sheet. Technicals add modest pressure due to a downtrend below major moving averages, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Low leverage / stronger latest balance sheet
The 2025 balance sheet shows zero debt and a large equity base, reducing near-term refinancing and interest burden. This durable strength provides financial flexibility to fund operations, pursue strategic options or weather revenue variability without immediate debt servicing pressure.
Negative Factors
Persistent unprofitability
Sustained multi-year losses and an extremely negative net margin signal the core business model is not yet profitable. Over the medium term this undermines retained earnings, forces dependence on external capital, and limits ability to invest in growth or margin-improving initiatives without dilution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / stronger latest balance sheet
The 2025 balance sheet shows zero debt and a large equity base, reducing near-term refinancing and interest burden. This durable strength provides financial flexibility to fund operations, pursue strategic options or weather revenue variability without immediate debt servicing pressure.
Read all positive factors
Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$69.51M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.01
Shares Outstanding315,958,040
10 Day Avg. Volume889,327
30 Day Avg. Volume1,029,223
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)6.82
Price to Sales (P/S)160.16
P/FCF Ratio-37.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Singular Health Group Ltd Business Overview & Revenue Model
Company Description
Singular Health Group Ltd, a medical technology company, develops and commercializes volumetric rendering platform (VRP) for the 3D and virtual reality (VR) visualization of anatomy using standard radiological imagery. It offers 3Dicom Viewer, a c...
How the Company Makes Money
null...
Singular Health Group Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.53K | 557.61K | 934.07K | 28.12K | 54.03K | 193.64K |
| Gross Profit | -2.01M | -86.22K | 516.36K | -3.58M | -2.11M | -1.62M |
| EBITDA | -8.14M | -6.27M | -2.58M | -4.52M | -5.65M | -2.86M |
| Net Income | -7.43M | -6.38M | -4.92M | -5.39M | -5.99M | -4.46M |
Balance Sheet | ||||||
| Total Assets | 12.55M | 14.21M | 2.35M | 3.00M | 2.14M | 5.43M |
| Cash, Cash Equivalents and Short-Term Investments | 11.06M | 13.68M | 1.45M | 691.51K | 1.14M | 4.14M |
| Total Debt | 113.71K | 0.00 | 218.45K | 2.51M | 85.66K | 147.59K |
| Total Liabilities | 856.60K | 1.11M | 909.59K | 2.94M | 391.50K | 345.10K |
| Stockholders Equity | 11.69M | 13.10M | 1.44M | 61.89K | 1.75M | 5.08M |
Cash Flow | ||||||
| Free Cash Flow | -4.38M | -2.37M | -2.51M | -2.49M | -2.92M | -2.22M |
| Operating Cash Flow | -4.23M | -2.34M | -2.44M | -2.46M | -2.91M | -1.91M |
| Investing Cash Flow | -8.49M | 88.14K | -3.56K | -635.21K | -17.12K | -610.57K |
| Financing Cash Flow | 6.36M | 14.48M | 3.21M | 2.65M | -69.25K | 6.52M |
Singular Health Group Ltd Technical Analysis
Neutral
0.26
Price Trends
0.23
Positive
0.25
Negative
0.27
Negative
Market Momentum
<0.01
Negative
54.76
Neutral
85.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SHG, the sentiment is Neutral. The current price of 0.26 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.23, and below the 200-day MA of 0.27, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.76 is Neutral, neither overbought nor oversold. The STOCH value of 85.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:SHG.
Singular Health Group Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$147.72M | 26.51 | 4.37% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$65.80M | -6.28 | -23.86% | ― | 15.99% | 22.05% | |
44 Neutral | AU$39.24M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$69.51M | -6.64 | -59.96% | ― | ― | ― | |
43 Neutral | AU$31.35M | -3.13 | -1009.84% | ― | 25.98% | 22.10% |
* Healthcare Sector Average
AU:SHG
Singular Health Group Ltd
0.22
-0.07
-24.14%
AU:M7T
Mach7 Technologies
0.28
-0.05
-15.15%
AU:BMT
Beamtree Holdings Ltd
0.14
-0.08
-38.64%
AU:ALC
Alcidion Group Limited
0.11
0.03
37.50%
AU:PCK
PainChek Ltd
0.15
-0.19
-55.88%
Singular Health Group Ltd Corporate Events
Singular Health Secures US$500,000 as PNS Expands Use of 3DICOM MD
Apr 21, 2026
Singular Health Group has received US$500,000 from U.S.-based Provider Network Solutions under a binding enterprise agreement linked to the deployment of its 3DICOM MD medical imaging licences. The payment follows the rollout of an additional 500 ...
Singular Health Raises Capital Through Exercise of Unlisted Options
Apr 9, 2026
Singular Health Group has issued 272,728 new fully paid ordinary shares following the exercise of an equivalent number of unlisted options priced at $0.10 and expiring in June 2026, raising $27,272.80 in additional capital. The company confirmed t...
Singular Health Seeks ASX Quotation for Additional 272,728 Shares
Apr 9, 2026
Singular Health Group Ltd has applied to the ASX for quotation of 272,728 new fully paid ordinary shares under the code SHG, with an issue date of 9 April 2026. The securities arise from the exercise or conversion of existing options or other conv...
Singular Health Director Increases Direct Shareholding via On-Market Purchase
Mar 23, 2026
Singular Health Group has disclosed a change in director Howard Digby’s interests in the company’s securities, following an on-market purchase of additional ordinary fully paid shares. Digby acquired 41,666 shares for $10,000, increasi...
Singular Health Accelerates U.S. Rollout and Regulatory Wins as Imaging Platform Gains Traction
Jan 26, 2026
Singular Health Group reported a quarter of strong operational progress, highlighted by the continued rollout of its Provider Network Solution (PNS) contract in the U.S., where deployment of an additional 500 3DICOM MD licences is underway and tri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.